ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELLITUS

Abstract

Sodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption. In addition to the hypoglycemic effect, various pleiotropic effects are described for this group of drugs. This article describes the effects of four-week treatment of diabetic rats by sodium-glucose co-transporter type 2 inhibitor dapagliflozin on various metabolic parameters and renal morphofunctional changes. We obtained that the addition of dapagliflozin to insulin-treated rats with streptozotocin-induced diabetes reduced the severity of glomerulosclerosis, and albuminuria.

Keywords

• sodium-glucose co-transporter 2 inhibitors
• dapagliflozin
• diabetes mellitus
• renoprotective effects